PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population ...

Abstract Background Platelet Endothelial Aggregation Receptor 1 (PEAR1), a membrane protein highly expressed in platelets and endothelial cells, plays a role in platelet contact-induced activation, sustained platelet aggregation and endothelial function. Previous reports implicate PEAR1 rs12041331 as a variant influencing risk in patients with coronary heart disease. We investigated whether genetic variation in PEAR1 predicts cardiovascular outcome in a white population. Methods In 1938 participants enrolled in the Flemish Study on Environment, Genes and Health Outcomes (51.3% women; mean age... Mehr ...

Verfasser: Yang, Wen-Yi
Petit, Thibault
Cauwenberghs, Nicholas
Zhang, Zhen-Yu
Sheng, Chang-Sheng
Lutgarde Thijs
Salvi, Erika
Izzi, Benedetta
Vandenbriele, Christophe
Wei, Fang-Fei
Gu, Yu-Mei
Jacobs, Lotte
Citterio, Lorena
Carpini, Simona Delli
Barlassina, Cristina
Cusi, Daniele
Hoylaerts, Marc
Verhamme, Peter
Kuznetsova, Tatiana
Staessen, Jan
Dokumenttyp: Artikel
Erscheinungsdatum: 2017
Verlag/Hrsg.: Figshare
Schlagwörter: Medicine / Genetics / FOS: Biological sciences / Neuroscience / Biotechnology / Immunology / FOS: Clinical medicine / Mental Health
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-29476301
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dx.doi.org/10.6084/m9.figshare.c.3758147

Abstract Background Platelet Endothelial Aggregation Receptor 1 (PEAR1), a membrane protein highly expressed in platelets and endothelial cells, plays a role in platelet contact-induced activation, sustained platelet aggregation and endothelial function. Previous reports implicate PEAR1 rs12041331 as a variant influencing risk in patients with coronary heart disease. We investigated whether genetic variation in PEAR1 predicts cardiovascular outcome in a white population. Methods In 1938 participants enrolled in the Flemish Study on Environment, Genes and Health Outcomes (51.3% women; mean age 43.6 years), we genotyped 9 tagging SNPs in PEAR1, measured baseline cardiovascular risk factors, and recorded Cardiovascular disease incidence. For SNPs, we contrasted cardiovascular disease incidence of minor-allele heterozygotes and homozygotes (variant) vs. major-allele homozygotes (reference) and for haplotypes carriers vs. non-carriers. In adjusted analyses, we accounted for family clusters and baseline ...